2022년 12월 13일 11:03

GIセルがオプティアム·バイオテクノロジーズと契約を締結

GIセルはオプティアム·バイオテクノロジーズ株式会社（日本）と研究ライセンス／オプション契約を締結したと発表した。 契約に従い、オプティアム·バイオテクノロジーズはGIセルに対し、オプティアム·バイオテクノロジーズのEumbody System™で作製した抗血液腫瘍抗体...

2022년 12월 13일 10:52

GI CELL Enters Agreement with Optieum Biotechnologies

GI CELL, Inc. announced that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. (Japan). Under the agreement, Optieum Biotechnologies will provide GI CELL with scFv antibodies directed against hematologi...

2022년 11월 16일 11:06

GICELL Proves Excellent Anti-tumor Efficacy in Various Solid Tumor-bearing Animal Model

GICELL announced the data from the preclinical studies on T.O.P. NK (Tumor targeting, Optimally Primed NK), an allogeneic NK cell therapy which had been presented at the Society for Immunotherapy of Cancer (SITC) held in Boston, MA, US. The SITC i...

2022년 9월 1일 14:19

GICELL to Collaborate with HK inno.N on Research and Development for next-generation CAR-NK Therapy

GICELL announced research and development collaboration for allogeneic CAR-NK candidates with HK inno.N on August 29th, 2022. The companies plan to advance the development of numerous CAR-NK therapies by harnessing GICELL‘s outstanding research co...